1. American Association for the Study of Liver Diseases 2017 Unique patient populations: patients with HIV/HCV coinfection http://www.hcvguidelines.org/full-report/unique-patient-populations-patients-hivhcv-coinfection
2. Nephrotoxicity associated with concomitant use of ledipasvir-sofosbuvir and tenofovir in a patient with hepatitis C Virus and human immunodeficiency virus coinfection;Bunnell;Pharmacotherapy,2016
3. Centers for Disease Control and Prevention 2017 Viral hepatitis - CDC recommendations for specific populations and settings http://www.cdc.gov/hepatitis/populations/hiv.htm
4. Meta-analysis: increased mortality associated with hepatitis C in HIV-infected persons is unrelated to HIV disease progression;Chen;Clin Infect Dis,2009
5. Custodio JM Doyle EB Pang PS Das M Cao H Ma G 2015 Lack of drug interactions between boosted and unboosted TAF-based antiretroviral single-tablet regimens (E/C/F/TAF, R/F/TAF) and the anti-HCV single-tablet regimen ledipasvir/sofosbuvir